tiprankstipranks
Trending News
More News >

UCB announces FDA accepts sBLA for BIMZELX

UCB announced that the U.S. FDA has accepted for review the supplemental Biologics License Application for BIMZELX, an IL-17A and IL-17F inhibitor, for the treatment of adults with moderate-to-severe hidradenitis suppurativa. In addition, a second sBLA for the BIMZELX 2mL device presentations has also been accepted.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1